98%
921
2 minutes
20
Background: Congenital cytomegalovirus (CMV) is the leading infectious cause of birth defects in the United States. To better understand factors that may influence CMV transmission risk, we compared viral and immunological factors in healthy children and their mothers.
Methods: We screened for CMV IgG antibodies in a convenience sample of 161 children aged 0-47 months from the Atlanta, Georgia metropolitan area, along with 32 mothers of children who screened CMV-seropositive. We assessed CMV shedding via PCR using saliva collected with oral swabs (children and mothers) and urine collected from diapers using filter paper inserts (children only).
Results: CMV IgG was present in 31% (50/161) of the children. Half (25/50) of seropositive children were shedding in at least one fluid. The proportion of seropositive children who shed in saliva was 100% (8/8) among the 4-12 month-olds, 64% (9/14) among 13-24 month-olds, and 40% (6/15) among 25-47 month-olds (P for trend=0.003). Seropositive mothers had a lower proportion of saliva shedding (21% [6/29]) than children (P<0.001). Among children who were shedding CMV, viral loads in saliva were significantly higher in younger children (P <0.001); on average, the saliva viral load of infants (i.e., <12 months) was approximately 300 times that of two year-olds (i.e., 24-35 months). Median CMV viral loads were similar in children's saliva and urine but were 10-50 times higher (P<0.001) than the median viral load of the mothers' saliva. However, very high viral loads (> one million copies/mL) were only found in children's saliva (31% of those shedding); children's urine and mothers' saliva specimens all had fewer than 100,000 copies/mL. Low IgG avidity, a marker of primary infection, was associated with younger age (p=0.03), higher viral loads in saliva (p=0.02), and lower antibody titers (p=0.005).
Conclusions: Young CMV seropositive children, especially those less than one year-old may present high-risk CMV exposures to pregnant women, especially via saliva, though further research is needed to see if this finding can be generalized across racial or other demographic strata.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236433 | PMC |
http://dx.doi.org/10.1186/s12879-014-0568-2 | DOI Listing |
Ann Lab Med
September 2025
Department of Pediatrics, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea.
Background: is a major cause of community-acquired pneumonia (CAP) in children, with a rising incidence of macrolide resistance. Early diagnosis is crucial for reducing the disease burden; however, current diagnostic tools have limitations. We evaluated the diagnostic accuracy of serological assays and their performance based on symptom onset in children with CAP.
View Article and Find Full Text PDFFront Immunol
September 2025
Department of Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu, China.
Objective: This study evaluated trends in population immunity against measles, rubella, mumps, and varicella in Suqian City (2005-2024) using serological surveys (2019-2024) and incidence data, incorporating participants with known/unknown vaccination statuses to explore immunity dynamics amid evolving policies, and inform public health planning.
Methods: Serum samples from 541 (2019) and 506 (2024) healthy participants were analyzed for virus-specific IgG antibodies using ELISA. Disease incidence data were obtained from China's National Notifiable Disease Reporting System.
Lancet Reg Health West Pac
August 2025
State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen, Fujian, China.
Background: A safe and highly efficacious -produced HPV-16/18 bivalent vaccine (Cecolin®) offers a cost-effective cervical cancer prevention measure. Here, we report data on the long-term efficacy and immunopersistence up to 10 years post-vaccination.
Methods: In the Phase III clinical trial (NCT01735006), 7372 women were enrolled and randomly assigned to receive the HPV or control vaccine (hepatitis E vaccine).
PLOS Glob Public Health
September 2025
School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Workers in food processing industries are subject to many occupational health risks and disparities, but little is known about their risk of tickborne diseases. We examined a cohort of Latino individuals working in the meat packing, produce processing, and farming industries and their family members in central North Carolina, where incidence of tickborne infections is high. Blood samples were tested for IgG antibodies against Spotted Fever Group Rickettsiosis (SFGR) and Ehrlichia chaffeensis.
View Article and Find Full Text PDFPLOS Glob Public Health
August 2025
Department of International Health, International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
Post-campaign coverage surveys estimate the proportion of previously unvaccinated children vaccinated during supplementary immunization activities (SIA) but cannot address whether susceptible children seronegative to measles and rubella viruses were vaccinated during the SIA. We conducted a cross-sectional serosurvey nested within the November 2020 measles-rubella SIA in Zambia, systematically sampling children aged 9 months to 5 years at 30 SIA sites in Choma and Ndola Districts. A questionnaire administered to caregivers collected the child's demographic information and vaccination history.
View Article and Find Full Text PDF